These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 38690281)

  • 1. Highly variable timing renders immunotherapy efficacy and toxicity impractical biomarkers of one another in clinical practice.
    von Itzstein MS; Yang Y; Wang Y; Hsiehchen D; Sheffield TY; Fattah F; Popat V; Ahmed M; Homsi J; Dowell JE; Rashdan S; Lohrey J; Hammers HJ; Hughes RS; Wang T; Xie Y; Gerber DE
    Front Immunol; 2024; 15():1351739. PubMed ID: 38690281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis.
    Ngamphaiboon N; Ithimakin S; Siripoon T; Sintawichai N; Sriuranpong V
    BMC Cancer; 2021 Nov; 21(1):1275. PubMed ID: 34823493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer.
    Allouchery M; Lombard T; Martin M; Rouby F; Sassier M; Bertin C; Atzenhoffer M; Miremont-Salame G; Perault-Pochat MC; Puyade M;
    J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment.
    Muir CA; Clifton-Bligh RJ; Long GV; Scolyer RA; Lo SN; Carlino MS; Tsang VHM; Menzies AM
    J Clin Endocrinol Metab; 2021 Aug; 106(9):e3704-e3713. PubMed ID: 33878162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between immune-related adverse event timing and treatment outcomes.
    Hsiehchen D; Naqash AR; Espinoza M; Von Itzstein MS; Cortellini A; Ricciuti B; Owen DH; Laharwal M; Toi Y; Burke M; Xie Y; Gerber DE
    Oncoimmunology; 2022; 11(1):2017162. PubMed ID: 35003896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival Among Veterans Receiving Steroids for Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy.
    Van Buren I; Madison C; Kohn A; Berry E; Kulkarni RP; Thompson RF
    JAMA Netw Open; 2023 Oct; 6(10):e2340695. PubMed ID: 37906189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and Outcome of Neurologic Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Patients With Melanoma.
    Pepys J; Stoff R; Ramon-Gonen R; Ben-Betzalel G; Grynberg S; Frommer RS; Schachter J; Asher N; Taliansky A; Nikitin V; Dori A; Shelly S
    Neurology; 2023 Dec; 101(24):e2472-e2482. PubMed ID: 37652699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
    Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S
    Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoint inhibitors: maximizing benefit whilst minimizing toxicity.
    Fahey CC; Gracie TJ; Johnson DB
    Expert Rev Anticancer Ther; 2023 Jul; 23(7):673-683. PubMed ID: 37194222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors.
    Nuzzo PV; Pond GR; Abou Alaiwi S; Nassar AH; Flippot R; Curran C; Kilbridge KL; Wei XX; McGregor BA; Choueiri T; Harshman LC; Sonpavde G
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32234849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A scoping review of vasculitis as an immune-related adverse event from checkpoint inhibitor therapy of cancer: Unraveling the complexities at the intersection of immunology and vascular pathology.
    Lee CM; Wang M; Rajkumar A; Calabrese C; Calabrese L
    Semin Arthritis Rheum; 2024 Jun; 66():152440. PubMed ID: 38579593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer.
    Dolladille C; Ederhy S; Sassier M; Cautela J; Thuny F; Cohen AA; Fedrizzi S; Chrétien B; Da-Silva A; Plane AF; Legallois D; Milliez PU; Lelong-Boulouard V; Alexandre J
    JAMA Oncol; 2020 Jun; 6(6):865-871. PubMed ID: 32297899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges in diagnosis and management of neutropenia upon exposure to immune-checkpoint inhibitors: meta-analysis of a rare immune-related adverse side effect.
    Boegeholz J; Brueggen CS; Pauli C; Dimitriou F; Haralambieva E; Dummer R; Manz MG; Widmer CC
    BMC Cancer; 2020 Apr; 20(1):300. PubMed ID: 32290812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma.
    Abou Alaiwi S; Xie W; Nassar AH; Dudani S; Martini D; Bakouny Z; Steinharter JA; Nuzzo PV; Flippot R; Martinez-Chanza N; Wei X; McGregor BA; Kaymakcalan MD; Heng DYC; Bilen MA; Choueiri TK; Harshman LC
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32066646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation Between Immune-Related Adverse Events and Prognosis in Hepatocellular Carcinoma Patients Treated With Immune Checkpoint Inhibitors.
    Xu S; Lai R; Zhao Q; Zhao P; Zhao R; Guo Z
    Front Immunol; 2021; 12():794099. PubMed ID: 34950153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune-related adverse events in cancer patients being treated with immune checkpoint inhibitors.
    Byrne MM; Lucas M; Pai L; Breeze J; Parsons SK
    Eur J Haematol; 2021 Dec; 107(6):650-657. PubMed ID: 34453348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic gut microbiota changes in patients with advanced malignancies experiencing secondary resistance to immune checkpoint inhibitors and immune-related adverse events.
    Zeng Y; Shi Q; Liu X; Tang H; Lu B; Zhou Q; Xu Y; Chen M; Zhao J; Li Y; Qian J; Wang M; Tan B
    Front Oncol; 2023; 13():1144534. PubMed ID: 37114123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variation in the Assessment of Immune-Related Adverse Event Occurrence, Grade, and Timing in Patients Receiving Immune Checkpoint Inhibitors.
    Hsiehchen D; Watters MK; Lu R; Xie Y; Gerber DE
    JAMA Netw Open; 2019 Sep; 2(9):e1911519. PubMed ID: 31532516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of sequential immune checkpoint inhibitors after prior immune therapy.
    Awidi M; Connell B; Johnson D; Craven I; Ranjit R; Gil B; Dal'Bo N; Maher L; Daves SR; McDonald S; Gunturu KS
    J Cancer Res Clin Oncol; 2023 Jun; 149(6):2375-2382. PubMed ID: 35727369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy.
    Das S; Ciombor KK; Haraldsdottir S; Pumpalova Y; Sahin IH; Pineda G; Shyr Y; Lin EP; Hsu CY; Chu SK; Goff LW; Cardin DB; Bilen MA; Fisher GA; Wu C; Berlin J
    Oncologist; 2020 Aug; 25(8):669-679. PubMed ID: 31943525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.